Potential plasticity of T regulatory cells in pancreatic carcinoma in relation to disease progression and outcome

Vizio,Barbara; Novarino,Anna; Giacobino,Alice; Cristiano,Carmen; Prati,Adriana; Ciuffreda,Libero; Montrucchio,Giuseppe; Bellone,Graziella

doi:10.3892/etm.2012.553

Potential plasticity of T regulatory cells in pancreatic carcinoma in relation to disease progression and outcome

Authors:
- Barbara Vizio
- Anna Novarino
- Alice Giacobino
- Carmen Cristiano
- Adriana Prati
- Libero Ciuffreda
- Giuseppe Montrucchio
- Graziella Bellone
View Affiliations

Affiliations: Department of Clinical Physiopathology, University of Turin, Italy, Department of Medical Oncology, San Giovanni Battista Hospital, Turin, Italy
Published online on: April 18, 2012 https://doi.org/10.3892/etm.2012.553
Pages: 70-78

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

CD4+CD25+FoxP3+ regulatory T cells (Tregs) are understood to maintain peripheral tolerance to self-antigens and inhibit antitumor immune responses. However, compelling evidence suggests that, Tregs provide no anti-inflammatory protection in the tumor microenvironment, but rather contribute to a T helper 17 (Th17)‑driven pro-carcinogenic process. Using three‑color flow cytometry, we evaluated the percentage of circulating CD4+CD25+FoxP3+ Tregs in the peripheral blood of pancreatic carcinoma patients prior to and after chemotherapy [gemcitabine (GEM) alone, or GEM+oxaliplatin (GEMOX) or bevacizumab+capecitabine+radiotherapy (BEV+CAPE+RT)]. Correlations were sought between Treg counts and plasma levels of cytokines relevant to controlling the Treg/Th17 balance, i.e., interleukin (IL)‑23, IL‑17A, IL‑6 and transforming growth factor β 1 (TGF‑β1), as measured by ELISA and the clinical features of pancreatic cancer. Treg, IL‑6 and TGF‑β1 levels were higher in locally advanced and metastatic pancreatic carcinoma patients compared to controls. No parameter was correlated with disease stage except IL‑6. IL‑17A and TGF‑β1 were significantly associated with increased risk of poor prognosis. IL‑17A was positively correlated with IL‑23. Treg and IL‑6 levels decreased following GEM monochemotherapy, IL‑17A levels decreased after GEMOX, and IL‑6 levels were reduced subsequent to BEV+CAPE+RT treatment. IL‑23, IL‑17A and TGF‑β1 levels were significantly lower in patients responding to chemotherapy (partial remission/stable disease) than in non-responders to chemotherapy (progressive disease). These results suggest an impact of the Treg/Th17-balance in pancreatic carcinoma, highlighting the significance of TGF‑β1 and IL‑17A as potential prognostic and predictive indicators. Immunological changes induced by mono and/or combined chemotherapy indicate specific windows of opportunity for introducing integrative interventions on a new target in pancreatic cancer, i.e. IL‑17A, possibly improving survival in this highly lethal disease.

View Figures

View References

1	Laheru D and Jaffee EM: Immunotherapy for pancreatic cancer - science driving clinical progress. Nat Rev Cancer. 5:459–467. 2005. View Article : Google Scholar : PubMed/NCBI
2	Greer JB and Whitcomb DC: Inflammation and pancreatic cancer: an evidence-based review. Curr Opin Pharmacol. 9:411–418. 2009. View Article : Google Scholar : PubMed/NCBI
3	Sakaguchi S, Sakaguchi N, Asano M, Itoh M and Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 155:1151–1164. 1995.
4	Sakaguchi S and Powrie F: Emerging challenges in regulatory T cell function and biology. Science. 317:627–629. 2007. View Article : Google Scholar : PubMed/NCBI
5	Erdman SE, Rao VP, Olipitz W, et al: Unifying roles for regulatory T cells and inflammation in cancer. Int J Cancer. 126:1651–1665
6	Chen Z and O’Shea JJ: Th17 cells: a new fate for differentiating helper T cells. Immunol Res. 41:87–102. 2008. View Article : Google Scholar : PubMed/NCBI
7	Bettelli E, Carrier Y, Gao W, et al: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 441:235–238. 2006. View Article : Google Scholar
8	Boniface K, Blom B, Liu YJ and de Waal Malefyt R: From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited. Immunol Rev. 226:132–146. 2008. View Article : Google Scholar : PubMed/NCBI
9	Ferrone S and Whiteside TL: Tumor microenvironment and immune escape. Surg Oncol Clin N Am. 16:755–774. viii2007. View Article : Google Scholar : PubMed/NCBI
10	Bellone G, Turletti A, Artusio E, et al: Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol. 155:537–547. 1999. View Article : Google Scholar
11	Bellone G, Carbone A, Smirne C, et al: Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells. J Immunol. 177:3448–3460. 2006. View Article : Google Scholar : PubMed/NCBI
12	Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E and Grubeck-Loebenstein B: Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res. 9:606–612. 2003.PubMed/NCBI
13	Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H and Fujii H: Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res. 9:4404–4408. 2003.PubMed/NCBI
14	Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF and Korangy F: Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 65:2457–2464. 2005. View Article : Google Scholar : PubMed/NCBI
15	Viguier M, Lemaitre F, Verola O, et al: Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol. 173:1444–1453. 2004.
16	Liyanage UK, Moore TT, Joo HG, et al: Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 169:2756–2761. 2002. View Article : Google Scholar : PubMed/NCBI
17	North RJ and Bursuker I: Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells. J Exp Med. 159:1295–1311. 1984.
18	Hiura T, Kagamu H, Miura S, et al: Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression. J Immunol. 175:5058–5066. 2005. View Article : Google Scholar : PubMed/NCBI
19	Walker LS, Chodos A, Eggena M, Dooms H and Abbas AK: Antigen-dependent proliferation of CD4⁺ CD25⁺ regulatory T cells in vivo. J Exp Med. 198:249–258. 2003. View Article : Google Scholar : PubMed/NCBI
20	Yamagiwa S, Gray JD, Hashimoto S and Horwitz DA: A role for TGF-beta in the generation and expansion of CD4⁺CD25⁺ regulatory T cells from human peripheral blood. J Immunol. 166:7282–7289. 2001. View Article : Google Scholar : PubMed/NCBI
21	Curiel TJ, Coukos G, Zou L, et al: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 10:942–949. 2004. View Article : Google Scholar : PubMed/NCBI
22	Merlo A, Casalini P, Carcangiu ML, et al: FOXP3 expression and overall survival in breast cancer. J Clin Oncol. 27:1746–1752. 2009. View Article : Google Scholar : PubMed/NCBI
23	Schaefer C, Kim GG, Albers A, Hoermann K, Myers EN and Whiteside TL: Characteristics of CD4⁺CD25⁺ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer. 92:913–920. 2005.
24	Kono K, Kawaida H, Takahashi A, et al: CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother. 55:1064–1071. 2006.
25	Stein-Streilein J and Taylor AW: An eye’s view of T regulatory cells. J Leukoc Biol. 81:593–598. 2007.
26	Bellone G, Smirne C, Mauri FA, et al: Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival. Cancer Immunol Immunother. 55:684–698. 2006. View Article : Google Scholar : PubMed/NCBI
27	Lee YK, Mukasa R, Hatton RD and Weaver CT: Developmental plasticity of Th17 and Treg cells. Curr Opin Immunol. 21:274–280. 2009. View Article : Google Scholar : PubMed/NCBI
28	Kimura A and Kishimoto T: IL-6: regulator of Treg/Th17 balance. Eur J Immunol. 40:1830–1835. 2010. View Article : Google Scholar : PubMed/NCBI
29	Wrzesinski SH, Wan YY and Flavell RA: Transforming growth factor-beta and the immune response: implications for anticancer therapy. Clin Cancer Res. 13:5262–5270. 2007. View Article : Google Scholar : PubMed/NCBI
30	Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM and Stockinger B: TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 24:179–189. 2006. View Article : Google Scholar
31	Zhang JP, Yan J, Xu J, et al: Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol. 50:980–989. 2009. View Article : Google Scholar : PubMed/NCBI
32	Chen X, Wan J, Liu J, et al: Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer. 69:348–354
33	Kryczek I, Banerjee M, Cheng P, et al: Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 114:1141–1149. 2009. View Article : Google Scholar : PubMed/NCBI
34	Gaffen SL: An overview of IL-17 function and signaling. Cytokine. 43:402–407. 2008. View Article : Google Scholar : PubMed/NCBI
35	Langowski JL, Zhang X, Wu L, et al: IL-23 promotes tumour incidence and growth. Nature. 442:461–465. 2006. View Article : Google Scholar : PubMed/NCBI
36	Langowski JL, Kastelein RA and Oft M: Swords into plowshares: IL-23 repurposes tumor immune surveillance. Trends Immunol. 28:207–212. 2007. View Article : Google Scholar : PubMed/NCBI
37	Numasaki M, Fukushi J, Ono M, et al: Interleukin-17 promotes angiogenesis and tumor growth. Blood. 101:2620–2627. 2003. View Article : Google Scholar : PubMed/NCBI
38	Kortylewski M, Xin H, Kujawski M, et al: Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor micro-environment. Cancer Cell. 15:114–123. 2009. View Article : Google Scholar : PubMed/NCBI
39	Weaver CT, Harrington LE, Mangan PR, Gavrieli M and Murphy KM: Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity. 24:677–688. 2006. View Article : Google Scholar : PubMed/NCBI
40	Carbone A, Vizio B, Novarino A, et al: IL-18 paradox in pancreatic carcinoma: elevated serum levels of free IL-18 are correlated with poor survival. J Immunother. 32:920–931. 2009. View Article : Google Scholar : PubMed/NCBI
41	Bellone G, Carbone A, Busso V, et al: Antagonistic interactions between gemcitabine and 5-fluorouracil in the human pancreatic carcinoma cell line Capan-2. Cancer Biol Ther. 5:1294–1303. 2006. View Article : Google Scholar : PubMed/NCBI
42	Correale P, Rotundo MS, Del Vecchio MT, et al: Regulatory (FoxP3⁺) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J Immunother. 33:435–441
43	Suzuki E, Kapoor V, Jassar AS, Kaiser LR and Albelda SM: Gemcitabine selectively eliminates splenic Gr-1⁺/CD11b⁺ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. 11:6713–6721. 2005.PubMed/NCBI
44	Fengming K, Anscher MS, Zhiping X and Jirtle RL: Elevated circulating transforming growth factor beta1 (TGFβ1) levels decreased after radiotherapy in patients with lung cancer, cervical cancer and Hodgkin’s disease: a possible tumor marker. Int J Radiat Oncol Biol Phys. 32:2391995.
45	Fujimoto-Ouchi K, Onuma E, Shirane M, Mori K and Tanaka Y: Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models. Cancer Chemother Pharmacol. 59:807–815. 2007. View Article : Google Scholar : PubMed/NCBI
46	Gounaris E, Blatner NR, Dennis K, et al: T-regulatory cells shift from a protective anti-inflammatory to a cancer-promoting proinflammatory phenotype in polyposis. Cancer Res. 69:5490–5497. 2009. View Article : Google Scholar : PubMed/NCBI